Key Takeaways
- Steady quarter, pricing pressure persists: Generic volumes grew but price erosion continued, offset by raw material cost relief and Custom Synthesis momentum.
- A ₹700 cr long-term CS contract signals confidence: A new supply agreement with an MNC, backed by a dedicated facility, points to visible, multi-year CS growth starting in 2027.
- Kakinada Unit III is on the verge of production: The new facility will begin phase-wise commercialization in H2 FY25, adding capacity for both CS and future generic opportunities.
- Margins held up on backward integration: Gross margin resilience is a "fair assumption" because cost leadership through chemistry and process reinvention offsets price erosion.
- What to watch next quarter: The pace of Kakinada's operational start, any new CS project signings, and whether generic pricing pressure shows any sign of abating.
Custom Synthesis: The Growth Engine
- New long-term contract anchors visibility: A supply agreement with an MNC requires a ₹650–₹700 cr dedicated facility, operational by January 2027, with commercial offtake starting that year after a 2.5-year validation and regulatory cycle.
- Broad-based CS momentum: Growth is driven by new projects across all clinical phases, steady value from existing commercial projects, and emerging opportunities in the peptide space.
- Two large CS projects are now commercializing: These previously flagged projects are slowly contributing to revenue, adding to the steadily growing base CS portfolio.
- Contrast media engagement is wide: The company is working with all four innovators at various stages, though management declined to detail specific projects or volumes.
- CS inquiry pipeline is "phenomenal": Management described a substantial increase in inquiries across new therapeutic segments but declined to quantify it.
Dr. Kiran S. Divi: "All I can say is I'm working with all the 4 innovators. Okay? And we're at various stages with them."
Generic Business: Volume Up, Price Down
- Volume growth is intact: The company has not lost any business or market share; volumes are consistently increasing, with some molecules growing 20–30% as Divi's pursues market leadership.
- Price erosion is the headwind: Geopolitical situations are driving pricing pressure, not a loss of demand; management noted this cycle resembles the 2009-10 downturn and will stabilize over time.
- Raw material costs provided a buffer: The hit from price erosion was offset by lower raw material prices and other variable cost reductions, protecting margins.
- API inventory has normalized: Customer-end API stockpiling from COVID has "pretty much stabilized everywhere," removing a demand overhang.
- Future generics are queued up: Regulatory submissions are filed across multiple countries for products going off patent; seven molecules are identified for post-patent opportunities from FY25 over the next five years.
Dr. Kiran S. Divi: "It's very hard to say when this will stabilize. Sometimes it takes one year, sometimes it takes 2 years. This has happened in the past in the year 2009-10, so it's repeating again, but prices will stabilize over time."
Capacity Expansion: Kakinada & Beyond
- Unit III is starting phase-wise in H2 FY25: The Kakinada facility will begin with validation batches, then progress through regulatory approvals and inspections before full commercialization.
- Phase II planning is gated: Construction of the next phase will begin only after Phase I is fully commercialized or nearing that point.
- FY25 capex is ₹1,500–₹1,600 cr: This includes the ₹800 cr balance on Kakinada Phase I plus the ₹700 cr for the new dedicated CS facility.
- The new CS facility requires unique technology: Management stated the project involves a very specific technology requiring investment specific to that product, and it will be housed at one of the two regulated units.
Cost Leadership & Technology Moat
- Backward integration protects gross margin: For most large-volume molecules, in-house manufacturing of intermediates minimizes wastage and cuts costs, making a big dip in gross margin unlikely.
- Process reinvention is cultural: Management cited Naproxen, where continuous reinvention drove the price from $100 to sub-$40 over decades while maintaining viability.
- New technology lab is operational: A dedicated lab now houses flow chemistry, mechanochemistry, microwave technology, and spray dry techniques to drive efficiency and reduce costs further.
Dr. Kiran S. Divi: "When Divi's started in the year 1994-95, okay, the price of Naproxen was at $100... Then you keep reinventing yourself. And today, the price is where the price is, in the sub-$40s."
Portfolio Mix & Strategy
- CS and generics grow hand-in-hand: Management targets a roughly 50/50 mix, with a possible 5% variation either way; both segments are expected to grow together as they have historically.
- Double-digit growth is the expectation: Ex-COVID products already delivered double-digit growth this year, and the company expects that trajectory to continue.
- Future generics will contribute from FY26/FY27: New DMFs signed will start adding to revenue as products like Ticagrelor, Lacosamide, and Brivaracetam gain traction post-patent expiry.
- One or two molecules come off patent in FY25: A stream of patent expiries continues over the next three to four years, feeding the generic pipeline.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Kakinada Unit III start | Phase-wise production activity to commence | H2 FY25 (Q2–Q3) |
| New CS facility operational | Dedicated facility for long-term MNC supply agreement | January 2027 |
| CS project commercial offtake | Customer begins taking commercial quantities after validations and regulatory approvals | From 2027 |
| Future generics contribution | New DMFs start contributing to revenue | FY26/FY27 |
| FY25 capex | Approximately ₹1,500–₹1,600 cr (Kakinada Phase I balance + new CS facility) | FY25 |
| Double-digit growth | Ex-COVID business growth trajectory | Going forward |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated total income | ₹2,382 cr, vs ₹2,017 cr in Q4 FY23 |
| Constant currency growth | 21%, vs negative 2% for FY24 |
| Profit before tax | ₹713 cr |
| Profit after tax | ₹538 cr |
| Material consumption | ~39% of sales revenue |
| Product mix (Generics : Custom Synthesis) | 49% : 51%, vs 55% : 45% for FY24 |
| Exports share | ~89% of revenue, vs ~87% for FY24 |
| Nutraceutical business revenue | ₹188 cr, vs ₹724 cr for FY24 |
| Forex impact | Loss of ₹2 cr, vs gain of ₹30 cr for FY24 |
| Cash on books | ₹3,980 cr as of March 31 |
| Receivables | ₹2,156 cr as of March 31 |
| Inventories | ₹3,184 cr as of March 31 |
| Capital work in progress | ~₹778 cr as of March 31 |
| Capitalized assets during the quarter | ₹201 cr, vs ₹402 cr for FY24 |
| Custom Synthesis share shift | ~500 bps increase QoQ, from 46% in Q3 to 51% in Q4 (per an analyst's math) |
| Long-term supply agreement investment | ₹650 cr to ₹700 cr estimated, facility expected operational by January 2027 |
| Kakinada Phase I capex spent | ~₹700 cr out of ₹1,500 cr total Phase I |
| FY25 capex guidance | ₹1,500 cr to ₹1,600 cr, comprising Phase I balance and the new project (per an analyst's math) |
| Post-patent generic opportunities identified | 7 molecules from FY25 over the next 5 years, with 1 or 2 coming off patent in FY25 |